Previous 10 | Next 10 |
Artivion Obtains $350 Million in Senior Secured Credit Facilities PR Newswire Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities and Provide Flexibility to Further Optimize Capital Structure ATLANTA , Jan. 18, 2024...
2023-12-27 11:37:05 ET Summary Today we look at small medical device maker Artivion, Inc., which has seen a roller coaster ride in its stock over the past year. The company manufactures and distributes medical devices such as aortic stents and implantable human tissues. Manage...
2023-12-07 06:31:55 ET More on Artivion Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025 Artivion Non-GAAP EPS of $0.02 misses by $0.01, revenue of $87.9M beats by $3.58M Seeking Alpha’s Quant Rating on Artivion For f...
Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer PR Newswire Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA , Dec. 6, 2023 /PRNewsw...
2023-11-21 19:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Artivion Announces Completion of Enrollment in PERSEVERE Trial PR Newswire ATLANTA , Nov. 9, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enro...
2023-11-05 01:51:09 ET Artivion, Inc. (AORT) Q3 2023 Earnings Conference Call November 2, 2023 04:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Officer Ashley Lee - Executive Vice President and ...
2023-11-02 16:32:34 ET More on Artivion Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025 Historical earnings data for Artivion Financial information for Artivion For further details see: Artivion Non-GAAP EPS of $0.02 mi...
Artivion Reports Third Quarter 2023 Financial Results PR Newswire Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 12:00:05 ET Frank Takkinen from Loop Capital Markets issued a price target of $30.00 for AORT on 2024-07-02 08:49:00. The adjusted price target was set to $30.00. At the time of the announcement, AORT was trading at $26.015. The overall price target consensus ...
Artivion Amends Agreements with Endospan PR Newswire Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million , inclusive of loan off-set, and $100 m...
2024-06-19 19:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...